Collateral for a security interest recorded Apr 8, 2026 (Royal Bank of Canada).
Term ends Oct 24, 2027 · High confidence
20-year base term ended Oct 17, 2026
Held by Gen-Probe Incorporated
Filed Nov 8, 2013 as application 14/075,944 · Granted Dec 19, 2017
Base term plus 372 days of patent term adjustment (USPTO delay)
Today
2006
2027
Clock starts
Oct 17, 2006
Oct 17, 2006
Term ends
Oct 24, 2027
Oct 24, 2027
Granted
Dec 19, 2017
Dec 19, 2017
base term
patent term adjustment
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
372
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
None
Terminal disclaimer
No disclaimer on this record.
2 of 2
Maintenance fees paid
Two maintenance fees can end this term early, the ones due 3.5 and 7.5 years from grant; the third one's grace period runs past the term end. This counts the ones the record shows paid.
4
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term runs 372 days past its 20-year base term on prosecution delay. 2 of 2 maintenance fees are paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Oct 17, 2006, when application 11/582,770, the earliest non-provisional in its chain, was filed (this one was filed Nov 8, 2013) | Oct 17, 2026 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +372 days, USPTO patent term adjustment record | Oct 24, 2027 | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 2 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Oct 24, 2027 | High confidence |
This family
| Application 11/582,770 | Abandoned not computed | not computed |
| US 8,609,829 | In force Apr 2027 | Apr 2027 |
| US 9,845,509 | this patent Oct 2027 | Oct 2027 |
| US 10,626,470 | In force Dec 2026 | Dec 2026 |
The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jan 16, 2014 Reel 32059, frame 467 | Hologic, Inc.; Biolucent, LLC; Cytyc Corporation; Cytyc Surgical Products, Limited; Direct Radiography Corp.; Suros Surgical Systems, Inc.; Third Wave Technologies, Inc.; Gen-Probe Incorporated | Goldman Sachs Bank USA | Security Agreement |
| Jul 17, 2015 Reel 36126, frame 813 | Goldman Sachs Bank USA, as Collateral Agent | Hologic, Inc.; Cytyc Corporation; Cytyc Surgical Products, Limited Partnership; Direct Radiography Corp.; Suros Surgical Systems, Inc.; Biolucent, LLC; Third Wave Technologies, Inc.; Gen-Probe Incorporated | Security Interest Release Reel/Frame 032059 0467 |
| Jul 17, 2015 reel/frame not recorded | Goldman Sachs Bank USA, as Collateral Agent | Hologic, Inc. | Security Interest Release Reel/Frame 032059 0467 |
| Jul 17, 2015 reel/frame not recorded | Goldman Sachs Bank USA, as Collateral Agent | Cytyc Corporation | Security Interest Release Reel/Frame 032059 0467 |
| Jul 17, 2015 reel/frame not recorded | Goldman Sachs Bank USA, as Collateral Agent | Cytyc Surgical Products, Limited Partnership | Security Interest Release Reel/Frame 032059 0467 |
| Jul 17, 2015 reel/frame not recorded | Goldman Sachs Bank USA, as Collateral Agent | Direct Radiography Corp. | Security Interest Release Reel/Frame 032059 0467 |
| Jul 17, 2015 reel/frame not recorded | Goldman Sachs Bank USA, as Collateral Agent | Suros Surgical Systems, Inc. | Security Interest Release Reel/Frame 032059 0467 |
| Jul 17, 2015 reel/frame not recorded | Goldman Sachs Bank USA, as Collateral Agent | Biolucent, LLC | Security Interest Release Reel/Frame 032059 0467 |
| Jul 17, 2015 reel/frame not recorded | Goldman Sachs Bank USA, as Collateral Agent | Third Wave Technologies, Inc. | Security Interest Release Reel/Frame 032059 0467 |
| Jul 17, 2015 reel/frame not recorded | Goldman Sachs Bank USA, as Collateral Agent | Gen-Probe Incorporated | Security Interest Release Reel/Frame 032059 0467 |
| Aug 7, 2015 Reel 36307, frame 199 | Hologic, Inc.; Biolucent, LLC; Cytyc Corporation; Cytyc Surgical Products, Limited Partnership; Direct Radiography Corp.; Gen-Probe Incorporated; Gen-Probe Prodesse, Inc.; Suros Surgical Systems, Inc.; Third Wave Technologies, Inc. | Bank of America, N.A., as Collateral Agent | Security Agreement |
| Aug 21, 2017 Reel 43344, frame 599 | Bungo, Jennifer J.; Hogan, James J.; Pollner, Reinhold B.; Hudspeth, Marie K.; Kaplan, Shannon K.; Marlowe, Elizabeth M. | Gen-Probe Incorporated | Assignment of Assignor's Interest |
| Apr 8, 2026 Reel 75462, frame 440 | Biotheranostics, Inc.; Gen-Probe Incorporated; Gen-Probe Prodesse, Inc.; Cytyc Corporation; Suros Surgical Systems, Inc.; Gynesonics, Inc.; Bolder Surgical, LLC; Faxitron Bioptics, LLC; Health Beacons, Inc.; Hologic, Inc. | Royal Bank of Canada, as Collateral Agent | Security Interest |
| Apr 8, 2026 Reel 75926, frame 339 | Biotheranostics, Inc.; Gen-Probe Incorporated; Gen-Probe Prodesse, Inc.; Cytyc Corporation; Suros Surgical Systems, Inc.; Gynesonics, Inc.; Bolder Surgical, LLC; Faxitron Bioptics, LLC; Health Beacons, Inc.; Hologic, Inc. | Citibank, N.A., as Collateral Agent | Security Interest |
| Apr 28, 2026 Reel 75566, frame 39 | Bank of America, N.A., as Collateral Agent | Hologic, Inc., on Its Own Behalf and as Successor-by-Merger to Direct Radiography Corp.; Cytyc Corporation, on Its Own Behalf and as Successor-by-Merger to Biolucent, LLC; Cytyc Surgical Products, LLC, as Successor-by-Conversion to Cytyc Surgical Products, Limited Partnership; Gen-Probe Incorporated, on Its Own Behalf and as Successor-by-Merger to Third Wave Technologies, Inc.; Gen-Probe Prodesse, Inc.; Suros Surgical Systems, Inc. | Release of Security Interest |
| Apr 28, 2026 reel/frame not recorded | Bank of America, N.A., as Collateral Agent | Hologic, Inc., on Its Own Behalf and as Successor-by-Merger to Direct Radiography Corp. | Release of Security Interest |
| Apr 28, 2026 reel/frame not recorded | Bank of America, N.A., as Collateral Agent | Cytyc Corporation, on Its Own Behalf and as Successor-by-Merger to Biolucent, LLC | Release of Security Interest |
| Apr 28, 2026 reel/frame not recorded | Bank of America, N.A., as Collateral Agent | Cytyc Surgical Products, LLC, as Successor-by-Conversion to Cytyc Surgical Products, Limited Partnership | Release of Security Interest |
| Apr 28, 2026 reel/frame not recorded | Bank of America, N.A., as Collateral Agent | Gen-Probe Incorporated, on Its Own Behalf and as Successor-by-Merger to Third Wave Technologies, Inc. | Release of Security Interest |
| Apr 28, 2026 reel/frame not recorded | Bank of America, N.A., as Collateral Agent | Gen-Probe Prodesse, Inc. | Release of Security Interest |
| Apr 28, 2026 reel/frame not recorded | Bank of America, N.A., as Collateral Agent | Suros Surgical Systems, Inc. | Release of Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
Oct 2027
Term ends Oct 24, 2027. No further fees fall due before then
Note
The 372 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Citations
0
later US patents cite this one
That is below the median of utility patents granted in 2017 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.